AssetMark’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.02M Buy
30,640
+6,584
+27% +$513K ﹤0.01% 953
2026
Q2
$1.79M Buy
24,056
+3,266
+16% +$229K ﹤0.01% 979
2026
Q1
$1.54M Buy
20,790
+16,820
+424% +$1.22M ﹤0.01% 940
2025
Q4
$304K Sell
3,970
-448
-10% -$29.4K ﹤0.01% 1223
2025
Q3
$229K Buy
4,418
+1,608
+57% +$78.4K ﹤0.01% 1240
2025
Q2
$121K Sell
2,810
-52
-2% -$1.89K ﹤0.01% 1326
2025
Q1
$98.9K Sell
2,862
-112
-4% -$3.78K ﹤0.01% 1283
2024
Q4
$81.6K Sell
2,974
-444
-13% -$11.5K ﹤0.01% 1293
2024
Q3
$87K Buy
3,418
+156
+5% +$4.1K ﹤0.01% 1172
2024
Q2
$82.6K Buy
3,262
+433
+15% +$11.8K ﹤0.01% 1137
2024
Q1
$87.5K Sell
2,829
-102
-3% -$3.47K ﹤0.01% 1067
2023
Q4
$118K Buy
2,931
+935
+47% +$28.1K ﹤0.01% 1009
2023
Q3
$52.6K Buy
+1,996
New +$56.6K ﹤0.01% 1088

Other funds holding BBIO

AssetMark's BBIO Position: Q3 2026 in Review

AssetMark increased its BridgeBio Pharma (BBIO) stake by 27% in Q3 2026, buying an estimated $513K and bringing the position to 30,640 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #953.

AssetMark first reported a position in BBIO in Q3 2023 and has held it in 13 quarters since. 348 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • AssetMark held 30,640 shares of BridgeBio Pharma worth $2.02M as of Q3 2026.
  • AssetMark bought 6,584 BridgeBio Pharma shares in Q3 2026, an estimated $513K.
  • BridgeBio Pharma made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #953 holding.
  • AssetMark first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 13 quarters since.
  • 348 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.